Novonesis Achieves 8% Organic Sales Growth in First Three Quarters of 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Source: Yahoo Finance
Sales Growth: Novonesis achieved 8% organic sales growth in the first nine months of 2025, with a revised full-year outlook now set at 7-8%, up from the previous 6-8%.
Profitability and Market Performance: The company reported a 37.3% adjusted EBITDA margin, demonstrating strong profitability despite currency challenges, with notable growth in both emerging (12%) and developed markets (6%).
Strategic Focus: CEO Ester Baiget highlighted the company's commitment to strategic priorities and its positioning to meet 2030 targets, indicating mid-single-digit growth for Q4.
Financial Metrics: The adjusted net profit increased by 22%, with free cash flow before acquisitions reaching EUR 668.4 million, and a NIBD/EBITDA ratio of 2.0x.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
